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Abstract
Background: Risk factors for pancreatic cancer include a cluster of metabolic conditions such as obesity, hypertension,
dyslipidemia, insulin resistance, and type 2 diabetes. Given that these risk factors are correlated, separating out causal from
confounded effects is challenging. Mendelian randomization (MR), or the use of genetic instrumental variables, may facilitate
the identification of the metabolic drivers of pancreatic cancer.
Methods: We identified genetic instruments for obesity, body shape, dyslipidemia, insulin resistance, and type 2 diabetes in
order to evaluate their causal role in pancreatic cancer etiology. These instruments were analyzed in relation to risk using a
likelihood-based MR approach within a series of 7110 pancreatic cancer patients and 7264 control subjects using genome-wide
data from the Pancreatic Cancer Cohort Consortium (PanScan) and the Pancreatic Cancer Case-Control Consortium (PanC4).
Potential unknown pleiotropic effects were assessed using a weighted median approach and MR-Egger sensitivity analyses.
Results: Results indicated a robust causal association of increasing body mass index (BMI) with pancreatic cancer risk (odds
ratio [OR] ¼ 1.34, 95% confidence interval [CI] ¼ 1.09 to 1.65, for each standard deviation increase in BMI [4.6 kg/m2]). There was
also evidence that genetically increased fasting insulin levels were causally associated with an increased risk of pancreatic
cancer (OR¼1.66, 95% CI¼1.05 to 2.63, per SD [44.4 pmol/L]). Notably, no evidence of a causal relationship was observed for type
2 diabetes, nor for dyslipidemia. Sensitivity analyses did not indicate that pleiotropy was an important source of bias.
Conclusions: Our results suggest a causal role of BMI and fasting insulin in pancreatic cancer etiology.
Pancreatic cancer is usually asymptomatic at early stages and
presents at an advanced incurable stage with five-year survival
rates of around 5% (1). Population-based screening for pancreatic
cancer is not currently an option because of the lack of an accurate
screening biomarker (2). The identification of risk factors for pri-
mary prevention is therefore of major interest as a method to re-
duce the incidence and consequences of the disease.
Tobacco exposure and obesity are the only modifiable fac-
tors with convincing evidence to be considered causal risk fac-
tors for pancreatic cancer (3,4). A dose-response relationship
has been observed with cigarette smoking (5,6). Body mass
index (BMI) is also associated with a modest increase in risk,
estimated to be between 10% and 50% per five-unit BMI (kg/m2)
increment (7–9). Other related anthropometric and metabolic
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factors have also been reported with modest effect sizes, includ-
ing height and waist-to-hip ratio (8,10). Additionally, obesity is
linked to a cascade of metabolic conditions, including hyper-
cholesterolemia, hyperglycemia, insulin resistance, and type 2
diabetes. Cholesterol intake, higher glucose levels, hyperinsuli-
nemia, and type 2 diabetes status have all been identified as po-
tential pancreatic cancer risk factors (11–15). The clustering of
these conditions is often referred to as metabolic syndrome, al-
though the specific parameters that lead to an increase in pan-
creatic cancer risk are unclear (6,16).
Mendelian randomization (MR) is an analytical approach
based on instrumental variable analysis and uses gene variants
associated with the risk factors of interest as unconfounded
markers of those factors (17). Important assumptions in instru-
mental variable analysis are that the chosen genetic variants
are associated with the exposure of interest, they are not associ-
ated with any confounders, and they are not associated with
the cancer outcome via any pathway other than through the ex-
posure of interest (known as genetic pleiotropy) (18). Genetic
variants satisfying these three assumptions divide a study
population into subgroups that are analogous to treatment
arms in a randomized controlled trial, in that they differ sys-
tematically with respect to the exposure of interest, but not
with respect to confounders. If all the instrumental variable as-
sumptions are met, an association between the genetic variant
and the outcome implies that the risk factor of interest has a
causal effect on the outcome (19).
In this study, we used genetic variation associated with
obesity and other metabolic traits as unconfounded instru-
ments to investigate the causal relationship between these
metabolic exposures and pancreatic cancer in case and control
individuals of similar European origin. Genetic proxies for modi-
fiable exposures were identified in several large genome-wide
association studies (GWAS) of the risk factors of interest, and
these genetic proxies were tested for association in a total of
7110 pancreatic cancer cases and 7264 controls obtained from
the Pancreatic Cancer Cohort Consortium (PanScan) and
Pancreatic Cancer Case-Control Consortium (PanC4) (20–22) via
dbGaP (23). We applied two-sample MR, an approach that com-
bines summary statistics on the genetic variant to exposure and
genetic variant to outcome associations from different samples
(24,25) and provides estimates of the strength of the association
between exposure and outcome.
Methods
Genetic Instruments for Putative Risk Factors
Genetic instruments for each risk factor were single-nucleotide
polymorphisms (SNPs) independently (linkage disequilibrium
[LD] R2 measure < 0.2) associated with the trait at a genome-
wide level (P < 5x108) identified in the most recent and largest
GWAS results on that trait from samples of European ethnicity.
Results from the Genetic Investigation of ANthropometric
Traits (GIANT) consortium were used to identify genetic proxies
for height (26), BMI (27), and waist-to-hip ratio (28). High-density
and low-density lipoprotein cholesterol (HDL and LDL, respect-
ively), total cholesterol, and triglycerides were selected as lipid
profile components. Genetic loci influencing bloodstream levels
of these lipids were identified from GWAS data provided by the
Global Lipids Genetic Consortium (GLGC) (29). Similarly, data
from the Meta-Analysis of Glucose and Insulin related traits
Consortium (MAGIC) were used to identify genetic loci for
glycemic traits including fasting glucose, fasting insulin, and
two-hour-postchallenge glucose (30). Finally, genetic instru-
ments for type 2 diabetes were identified from a recent genetic
fine mapping study (31,32). For each identified SNP, the reported
effect allele size was for the allele associated with an increase
in the trait and expressed in one standard deviation of the trait
per allele (bGP), along with the standard error. For studies in
which the genetic effects were not originally reported in SD
units of the trait, they were recalibrated according to the mean
SD and weighted for sample size across the different case-
control samples. SNPs with ambiguous strand codification (A/T
or C/G) were replaced by SNPs in tight genetic linkage (LD R2 >
0.8) using the SNP Annotation and Proxy Search (SNAP; https://
www.broadinstitute.org/mpg/snap/ldsearch.php) or removed
from the analyses. The number of identified SNPs and proportion
of variance explained for each risk factor are detailed in Table 1.
Pancreatic Cancer Samples and Meta-analysis
GWAS data from pancreatic cancer samples were obtained from
the PanScan (12 studies) and PanC4 (10 studies) consortia
through the National Center for Biotechnology Information
database of Genotypes and Phenotypes (dbGaP; Study
Accession: phs000206.v3.p2 and phs000648.v1.p1; project refer-
ence #9314) (23) and were originally published in three different
sets called PanScan I (1788 cases and 1769 controls), PanScan II
(1696 cases and 1563 controls), and PanC4 (3626 PanC4 cases
and 3932 controls) (20–22). These samples comprised 7638 cases
and 7364 controls of European origin and were originally geno-
typed using Illuminia HumanHap550, Human610-Quad, and
HumanOmniExpressExome-8v1 arrays, respectively (Illumina
Inc. San Diego, CA). Detailed sample characteristics can be
observed in Supplementary Table 1 (available online). Initial
quality control steps and analyses were performed within each
publication set. After removing duplicates, related samples,
samples with sex discrepancy, and population outliers, 7110
cases and 7264 controls remained. Genotype imputation was
performed using the Michigan Imputation Server (33).
Genotypes were prephased using SHAPEIT v2 (34) and imputed
with Minimach v3 (35) using the Haplotype Reference
Consortium panel (36). After imputation, SNPs with imputation
quality (R2) lower than 0.7 were removed from the data sets.
Association statistics on pancreatic cancer risk were obtained
adjusting for age, sex, and statistically significant eigenvectors
for population stratification using R software. Association stat-
istics were also obtained for sex strata. Results from each set
were then combined using a fixed-effects inverse-SE approach
implemented in METAL (37), obtaining the pancreatic cancer
risk estimates (bGD) and SE. For each SNP used as an instrument
in this report, SNP to phenotype effect (bGP) and SNP to disease
effect (bGD) can be observed in Supplementary Table 2 (available
online).
Statistical Analyses
Power Assessment
Power calculations on MR analyses were performed for four
genetic instruments, based on the number of cases and controls
of the pooled sample (38). The four genetic instruments corres-
ponded to different explained proportions of phenotype vari-
ance (1.5% representing waist-to-hip ratio, fasting insulin, and
glucose at two hours postchallenge; 2.7% for BMI; 5% represent-
ing fasting glucose and type 2 diabetes; and 10% as a lower
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threshold of lipid parameters) (Table 1). Power calculations can
be observed in Supplementary Figure 1 (available online).
Additionally, we assessed our power to validate previously
observed risk increase from potential risk parameters analyzed
in this study. Our sample had a high power to validate previ-
ously observed risk increases for BMI (86.3% of power for a risk
increase of 39% per SD increase) and type 2 diabetes (99.5% for
an increase of 40%), although it was only modestly powered for
height (57.7% for an increase of 10%) and fasting glucose (65.5%
for a 21% risk increase), and underpowered for a risk increase of
19% from waist-to-hip ratio (21.2%) (Supplementary Table 3,
available online).
Mendelian Randomization Analyses
The causal effect on pancreatic cancer was estimated using a
likelihood-based approach (24) for the pooled sample, after strat-
ifying by publication set (PanScan I, PanScan II, and PanC4) and for
sex. The MR likelihood-based approach is considered the most ac-
curate method to estimate causal effects when there is a continu-
ous log-linear association between risk factor and disease risk.
The resulting odds ratios (ORs) and 95% confidence intervals (CIs)
provided an estimate of relative risk caused by each SD increase
in the trait (Table 1). We also investigated the between-study and
between-sex heterogeneity of causal effects, estimating the per-
centage of variance that is attributable to study or sex heterogen-
eity (I2 statistic), the Q statistic for heterogeneity, and its P value
(PHeterogeneity), assuming a fixed-effect model of 2 degrees of free-
dom for study heterogeneity and 1 degree of freedom for sex het-
erogeneity. This was done using the meta R package (R project). To
evaluate the potential effect of pleiotropy on the likelihood risk es-
timates, we used different complementary approaches. Because
genetic variants for metabolic factors can be confounded by BMI
effect, a likelihood-based approach was performed for the
nonobesity exposures excluding the genetic variants known to be
also robustly associated with BMI. Additionally, two approaches,
namely the weighted median estimation (39) and the MR-Egger
approach (40), were performed on the initial set of genetic variants
to detect bias due to pleiotropy from unknown origin. The
weighted median estimator is the median of a distribution in
which Wald ratio estimates have been ordered and represent per-
centiles of this distribution (39), which is less sensitive to the effect
of pleiotropic variants behaving as outliers. On the other hand, the
MR-Egger approach performs a weighted linear regression of the
SNP to disease effects (bGD) on the SNP to phenotype effects (bGP).
In this test, the analyses of the regression intercept detects an
overall directional pleiotropic contribution of weak instrumental
SNPs on the risk estimate (assuming that any pleiotropic contribu-
tion biasing the risk estimation is acting in the same direction)
(40). For each potential risk factor, a scatter plot of the SNP risk in-
crease (exp(bGD/bGP)) against the strength of instrumental SNPs
(bGP/SEGD) was constructed, providing a funnel plot for visual as-
sessment of asymmetry of instrumental causal estimates. These
plots were generated using the ggplot2 R package (R Project).
Finally, in order to explore the causal effect of mechanistic
pathways in which genetic instruments clustered, for those risk
factors with more than 50 (ie, height, BMI, and lipid parameters),
the genetic instrument set was divided in subsets according to
mechanistic pathways as described in the original GWAS study
(with a minimum of five SNPs in each subset). These genetic in-
strument subsets were subsequently tested for their association
with pancreatic cancer using the MR likelihood-based approach.
All statistical tests were two-sided, a P value of less than .05
was considered statistically significant, and a Bonferroni correction
for multiple testing was applied for mechanistic pathways tests.
Results
MR Likelihood-Based Results
The genetic instrument for BMI comprising 95 instrumental
SNPs indicated that the effect of each SD increase in BMI (4.6 kg/
m2) increased pancreatic cancer risk (OR ¼ 1.34, 95% CI ¼ 1.09 to
1.65) (Figure 1). Stratified analyses by publication set and sex
suggested consistent odds ratio estimates (OR ranging from 1.25
to 1.48, PHeterogeneity > .79) (Figure 2). The genetic instrument for
height (558 SNPs) did not indicate any causal association with
risk (OR¼ 1.03, 95% CI¼ 0.95 to 1.12), nor for waist-to-hip ratio
(34 SNPs; OR¼ 1.12, 95% CI¼ 0.78 to 1.60) (Figure 1;
Supplementary Figure 2, A and B, available online, for the strati-
fied analyses). Instruments for the lipid traits, including HDL,
LDL, total cholesterol, and triglycerides, did not indicate an ef-
fect on overall risk of pancreatic cancer (Figure 1). Heterogeneity
was not observed in the subgroup analyses (see, for instance,
Supplementary Figure 2, C and D, available online, for stratified
analyses on HDL and triglycerides, respectively). Four potential
risk factors related to diabetes were evaluated, including type 2
Table 1. Potential risk factors for pancreatic cancer, number of identified instrumental SNPs, phenotype distribution (mean and SD) in the
discovery sample, and percentage of the phenotype variance explained by the instruments*
Phenotype No. of SNPs Mean 6 SD Units Variance explained, % Consortium Reference No.
Height 567 169.9 6 6.9 cm 16.0 GIANT 26
Body mass index 96 27.0 6 4.6 kg/m2 2.7 GIANT 27
Waist-to-hip ratio 34 1.1 6 0.1 cm/cm 1.4 GIANT 28
High-density cholesterol 70 53.3 6 15.5 mg/dL 13.7 GLGC 29
Low-density cholesterol 54 133.6 6 38 mg/dL 14.6 GLGC 29
Total cholesterol 72 213.28 6 42.6 mg/dL 15.0 GLGC 29
Triglycerides 40 140.85 6 87.8 mg/dL 11.7 GLGC 29
Fasting glucose 37 5.2 6 0.8 mmol/L 4.8 MAGIC 30
Fasting insulin 17 56.9 6 44.4 pmol/L 1.2 MAGIC 30
2-h-postchallenge glucose 9 5.6 6 1.7 mmol/L 1.7 MAGIC 30
Type 2 diabetes 44 5.7 DIAGRAM 31,32
*DIAGRAM ¼ DIAbetes Genetics Replication And Meta-analysis; GIANT ¼ Genetic Investigation of ANthropometric Traits; GLGC ¼ Global Lipids Genetic Consortium;
MAGIC ¼Meta-Analysis of Glucose and Insulin related traits Consortium; SNP ¼ single-nucleotide polymorphism.
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diabetes, fasting glucose, fasting insulin, and two-hour-
postchallenge glucose (Table 1). The genetic instrument for type
2 diabetes status was not associated with pancreatic cancer risk
(OR¼ 1.03, 95% CI¼ 0.95 to 1.11) (Figure 1), although results by
sex indicated a potential role among men (OR¼ 1.08, 95% CI¼
0.98 to 1.20) but not for women (OR¼ 0.96, 95% CI¼ 0.86 to 1.08)
(Figure 3A). In contrast, each SD increase in fasting insulin was
associated with an increased risk of pancreatic cancer
(OR¼ 1.66, 95% CI¼ 1.05 to 2.63) (Figure 1), with little evidence
for between-study heterogeneity (Figure 3B). Conversely, the ef-
fect of fasting insulin appeared to differ by sex, the odds ratio
estimate being 2.59 in men (95% CI¼ 1.39 to 4.80) and 0.94 in
women (95% CI¼ 0.48 to 1.85; I2 ¼ 78.7%, PHeterogeneity ¼ .03)
(Figure 3B). Finally, there was no evidence that the genetic in-
struments for the glycemic traits were associated with pancre-
atic cancer risk (Figure 1; Supplementary Figures 2, E and F,
available online, for the stratified analyses).
Likelihood-Based Approach Excluding SNPs Robustly
AssociatedWith BMI
After removing BMI SNPs, four SNPs were dropped in analyses
for type 2 diabetes, three for HDL and fasting insulin, two for
two-hour-postchallenge glucose, and one for LDL, total choles-
terol, triglycerides, and fasting glucose. This analysis resulted in
Figure 1. Forest plot of risk increase on pancreatic cancer for each standard deviation increase in the exposure. *Likelihood-based Mendelian randomization test. P val-
ues are two-sided. CI ¼ confidence interval; OR ¼ odds ratio.
Figure 2. Forest plot of risk increase on pancreatic cancer for each standard deviation increase in body mass index stratified by publication sets and sex. *Likelihood-
based Mendelian randomization test. P values are two-sided. †Heterogeneity Q test. Pheterogeneity values are two-sided. BMI ¼ body mass index; CI ¼ confidence interval;
I2 ¼ index of between-strata heterogeneity; OR ¼ odds ratio; Q ¼ statistic for between-strata heterogeneity.
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odds ratio estimates that were similar to the initial estimates
(Supplementary Table 4, available online), although the effect of
fasting insulin was attenuated (OR¼ 1.26, 95% CI¼ 0.73 to 2.16).
However, in the analyses stratified by sex, the fasting insulin ef-
fect on pancreatic cancer remained increased in men (OR¼ 2.27,
95% CI¼ 1.09 to 4.71) but not in women (OR¼ 0.64, 95% CI¼ 0.29
to 1.42).
Weighted Median MR Results
Using the weighted median MR approach, the corresponding es-
timation of the risk increase was also increased for BMI
(OR¼ 1.70, 95% CI¼ 1.22 to 2.36) and fasting insulin (OR¼ 1.94,
95% CI¼ 1.02 to 3.68) (Supplementary Table 5, available online),
indicating that the original likelihood-based results were not
due to a small subgroup of variants with a strong pleiotropic
effect.
MR-Egger Test
Finally, the analysis of the intercept in the MR-Egger test (pro-
viding an estimate of directional pleiotropy) for the different in-
struments suggested that directional pleiotropy was not an
important phenomenon for the observed associations with BMI
or fasting insulin. There was some evidence of directional plei-
otropy on the overall risk estimation for triglycerides (intercept
estimate ¼ 0.02, 95% CI¼ 0.01 to 0.04) (Supplementary Table 5,
available online). MR-Egger regression suggested an inverse as-
sociation of triglycerides with risk of pancreatic cancer
(OR¼ 0.63, 95% CI¼ 0.48 to 0.83; for an increase of 87.8 mg/dL)
(Supplementary Table 5, available online).
The distribution of risk estimates of BMI SNPs along with
the likelihood-based and weighted median risk causal effects
for BMI can be observed in the funnel plot of Figure 4. In this
figure, the overall symmetrical distribution suggests a lack of
pleiotropy on the BMI causal estimates. In contrast, the corres-
ponding funnel plot for triglycerides (Figure 5) showed
evidence of a pleiotropic effect of some instrumental SNPs for
triglycerides on the initial risk estimate detected in the
MR-Egger analysis (asymmetry of instrumental risk estima-
tions toward positive effects). For type 2 diabetes, the distribu-
tion of SNP risk estimates showed symmetry around unity
(Figure 6). Finally, sex discrepancies on causal effects for fast-
ing insulin on pancreatic cancer can be observed in Figure 7, A
and B, for men and women, respectively. Funnel plots for the
other tested parameters were included in Supplementary
Figure 3 (available online).
Figure 3. Forest plots of risk increase on pancreatic cancer for type 2 diabetes status (A) and for each standard deviation increase in fasting insulin levels (B), stratified
by publication sets and sex. *Likelihood-based Mendelian randomization test. P values are two-sided. †Heterogeneity Q test. Pheterogeneity values are two-sided. CI ¼ con-
fidence interval; I2 ¼ index of between-strata heterogeneity; OR ¼ odds ratio; Q ¼ statistic for between-strata heterogeneity.
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Figure 4. Funnel plot of risk estimates of body mass index (BMI)–instrumental single-nucleotide polymorphisms (SNPs) on pancreatic cancer against instrumental
strength. Instrumental strength is SNP to pancreatic cancer effect corrected by SNP to BMI standard error of the effect. X-axis is in logarithmic scale. P values are two-
sided, Mendelian randomization test. BMI ¼ Body mass index; CI ¼ confidence interval; OR ¼ odds ratio.
Figure 5. Funnel plot of risk estimates of triglyceride–instrumental single-nucleotide polymorphisms (SNPs) on pancreatic cancer against instrumental strength.
Instrumental strength is SNP to pancreatic cancer effect corrected by SNP to triglycerides standard error of the effect. X-axis is in logarithmic scale. SNPs also robustly
associated with BMI (1 SNPs) are depicted as triangles. P values are two-sided, Mendelian randomization test. CI ¼ confidence interval; OR ¼ odds ratio.
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MR Likelihood-Based Results for Mechanistic Pathway
Components of Risk Factors
Genetic instruments clustered in 127 different mechanistic
pathways for height, 19 for BMI, three for HDL and LDL, four for
total cholesterol, and one for triglycerides. No mechanistic
pathway component appeared associated with pancreatic can-
cer risk after Bonferroni correction for multiple testing (P < 3.2
x10-4; lowest P ¼ .02) (Supplementary Table 6, available online).
Discussion
We have used data from large GWA studies on pancreatic can-
cer to evaluate the causal relevance of metabolic risk factors
within an MR framework. Our results support higher BMI as a
causal risk factor of pancreatic cancer, as well a potential causal
role of higher insulin, in particular among men. Conversely, our
results provided little support for a causal role of type 2 diabetes
or dyslipidemia in pancreatic cancer.
For BMI, we observed a 34% increase in pancreatic cancer
risk per SD increase (4.6 kg/m2). This is similar to the associ-
ations reported in observational studies using measured BMI
(7–9). In the case of height and waist-to-hip ratio, our analyses
did not detect higher risk effects than those previously observed
in the literature, for which our sample was underpowered.
Thus, our analyses of the relationship between height and
waist-to-hip ratio and pancreatic cancer cannot be considered
conclusive. For fasting insulin, we observed a 66% increased risk
of pancreatic cancer per SD increase (44.4 pmol/L), although the
strength of the association was marginal (P ¼ .03), especially if
the number of comparisons is considered. This association was
driven by a strong risk increase in men (P ¼ .003), whereas no
association was seen in women. Conversely, we did not identify
any risk increase for type 2 diabetes, nor for glucose levels.
Finally, we found little evidence of a causal relationship be-
tween lipid parameters and pancreatic cancer risk. However,
potential modest effects cannot be discarded, especially in the
case of triglycerides.
Obesity and additional metabolic factors are associated with
risk of several cancers (16), but traditional observational studies
have had difficulties disentangling and establishing causality
for the individual factors. Our results would support a direct
role for obesity and the insulin pathway in pancreatic cancer.
One hypothesis that would be in line with our results is that
obesity leads to increasing insulin levels and risk of hyperinsuli-
nemia, which in turns decreases insulin-like growth factor (IGF)
binding proteins, thus allowing increasing circulating levels of
insulin-like growth factor I (IGF1) (41–43). Both insulin and IGF1
are promoters of cell proliferation and inhibition of apoptosis in
tumor cells (16,41,44,45). The interaction of the insulin pathway
with sex hormones could explain the observed sex differences
in terms of risk and deserves further investigation (43). Our re-
sults also lend further support to classical epidemiological stud-
ies showing an association between elevated circulating insulin
and pancreatic cancer risk, especially in men (13), but little evi-
dence for a role of type 2 diabetes. The latter observation would
be in line with some studies suggesting that the observational
association between type 2 diabetes risk may be due to reverse
causation, that is, type 2 diabetes reflecting an early manifest-
ation of pancreatic cancer, rather than being a causal factor
(14,15). As our results suggest a potential important causal role
of fasting insulin, the occurrence of hyperinsulinemia in early
type 2 diabetes (46) would also be in line with insulin acting as a
confounder for any observed association between type 2 dia-
betes and pancreatic cancer risk.
The main limitation in MR studies is the potential violation
of assumptions of linearity and pleiotropy. Firstly, our MR ana-
lysis assumes a linear relation between each genetic instrument
Figure 6. Funnel plot of risk estimates of type 2 diabetes–instrumental single-nucleotide polymorphisms (SNPs) on pancreatic cancer against instrumental strength.
Instrumental strength is SNP to pancreatic cancer effect corrected by SNP to type 2 diabetes standard error of the effect. X-axis is in logarithmic scale. SNPs also ro-
bustly associated with BMI (4 SNPs) are depicted as triangles. P values are two-sided, Mendelian randomization test. CI ¼ confidence interval; OR ¼ odds ratio.
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and the risk factor of interest, as well as a log-linear association
between the risk factors and pancreatic cancer risk. It is not pos-
sible to test these assumptions with current data, but deviations
from these assumptions would result in reduced statistical
power in risk analyses, rather than generating spurious associ-
ations. However, the estimated effects may not be representa-
tive of the effects of the traits in the extremes of their
distributions. Therefore, some caution is needed for the general
interpretation of the results. In regards to pleiotropy, the use of
complementary MR approaches and the visual inspection of
funnel plots allowed us to evaluate the presence of pleiotropic
effects on the instrumental SNPs. This is of particular concern
for metabolic traits, where potential genetic confounding from
BMI could bias initial estimates. Our additional analyses did
not, however, indicate that pleiotropic effects were biasing the
risk associations of BMI and fasting insulin.
In conclusion, using a two-sample MR approach, this study
assessed a range of metabolic factors in relation to pancreatic
Figure 7. Funnel plots of risk estimates of fasting insulin–instrumental single-nucleotide polymorphisms (SNPs) on pancreatic cancer in male (A) and female (B) against
instrumental strength. Instrumental strength is SNP to pancreatic cancer effect corrected by SNP to fasting insulin standard error of the effect. X-axis is in logarithmic
scale. SNPs also robustly associated with BMI (three SNPs) are depicted as triangles. P values are two-sided, Mendelian randomization test. CI ¼ confidence interval; OR
¼ odds ratio.
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cancer risk. Our results suggest that increases in BMI and fast-
ing insulin are causally associated with an increased risk of
pancreatic cancer. These findings provide important novel evi-
dence on the etiology of pancreatic cancer.
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